Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle cell disease and acute chest syndrome

Marie-Hélène Odièvre¹, Charles de Marcellus², Hubert Ducou Le Pointe³, Slimane Allali⁴, Anne-Sophie Romain¹, Jenny Youn¹, Jessica Taytard⁵, Nadia Nathan⁵, Harriet Corvol⁵

Affiliations

¹ Department of General Pediatrics, Center for Sickle Cell Disease, Trousseau Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris, France.
² Pediatric Intensive Care Unit, Necker-Enfants-Malades Hospital, AP-HP, Université de Paris, Paris, France.
³ Imaging Department, Trousseau Hospital, AP-HP, Sorbonne Université, Paris, France.
⁴ Department of General Pediatrics and Pediatric Infectious Diseases, Reference Center for Sickle Cell Disease, Necker-Enfants-Malades Hospital, AP-HP, Université de Paris, Paris, France.
⁵ Pediatric Pulmonology Department, Trousseau Hospital, AP-HP, Sorbonne Université, Paris, France.

PMID: 32358817
PMCID: PMC7267654
DOI: 10.1002/ajh.25855

Comment

Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle cell disease and acute chest syndrome

Marie-Hélène Odièvre et al. Am J Hematol. 2020 Aug.

. 2020 Aug;95(8):E192-E194.

doi: 10.1002/ajh.25855. Epub 2020 May 16.

Authors

Marie-Hélène Odièvre¹, Charles de Marcellus², Hubert Ducou Le Pointe³, Slimane Allali⁴, Anne-Sophie Romain¹, Jenny Youn¹, Jessica Taytard⁵, Nadia Nathan⁵, Harriet Corvol⁵

Affiliations

¹ Department of General Pediatrics, Center for Sickle Cell Disease, Trousseau Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris, France.
² Pediatric Intensive Care Unit, Necker-Enfants-Malades Hospital, AP-HP, Université de Paris, Paris, France.
³ Imaging Department, Trousseau Hospital, AP-HP, Sorbonne Université, Paris, France.
⁴ Department of General Pediatrics and Pediatric Infectious Diseases, Reference Center for Sickle Cell Disease, Necker-Enfants-Malades Hospital, AP-HP, Université de Paris, Paris, France.
⁵ Pediatric Pulmonology Department, Trousseau Hospital, AP-HP, Sorbonne Université, Paris, France.

PMID: 32358817
PMCID: PMC7267654
DOI: 10.1002/ajh.25855

No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no potential conflict of interest.

Comment on

Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab.
De Luna G, Habibi A, Deux JF, Colard M, Pham Hung d'Alexandry d'Orengiani AL, Schlemmer F, Joher N, Kassasseya C, Pawlotsky JM, Ourghanlian C, Michel M, Mekontso-Dessap A, Bartolucci P. De Luna G, et al. Am J Hematol. 2020 Jul;95(7):876-878. doi: 10.1002/ajh.25833. Epub 2020 May 12. Am J Hematol. 2020. PMID: 32282956 Free PMC article. No abstract available.

References

1. De Luna G, Habibi A, Deux JF, et al. Rapid and severe Covid‐19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab. Am J Hematol. 2020. 10.1002/ajh.25833. - DOI - PMC - PubMed
1. Beerkens F, John M, Puliafito B, Corbett V, Edwards C, Tremblay D. COVID‐19 pneumonia as a cause of acute chest syndrome in an adult sickle cell patient. Am J Hematol. 2020. 10.1002/ajh.25809. - DOI - PubMed
1. Nur E, Gaartman AE, van Tuijn CFJ, Tang MW, Biemond BJ. Vaso‐occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID‐19). Am J Hematol. 2020;95(6):725‐726. - PMC - PubMed
1. Cellina M, Orsi M, Bombaci F, Sala M, Marino P, Oliva G. Favorable changes of CT findings in a patient with COVID‐19 pneumonia after treatment with tocilizumab. Diagn Interv Imaging. 2020;101:323‐324. - PMC - PubMed
1. Conran N, Belcher JD. Inflammation in sickle cell disease. Clin Hemorheol Microcirc. 2018;68(2–3):263‐299. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle cell disease and acute chest syndrome

Affiliations

Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle cell disease and acute chest syndrome

Authors

Affiliations

Conflict of interest statement

Comment on

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources